✦ LIBER ✦

Improvements in skeletal manifestations in gaucher disease Type 1 patients receiving oral eliglustat during a phase 2 trial

✍ Scribed by Ravi Kamath; Elena Lukina; Nora Watman; Marta Dragosky; Marcelo Iastrebner; Gregory M. Pastores; Elsa Avila Arreguin; Hanna Rosenbaum; Mici Phillips; Mathilde Kaper; Ana Cristina Puga; M. Judith Peterschmitt; Daniel I. Rosenthal

Book ID: 116989175
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 58 KB
Volume: 102
Category: Article
ISSN: 1096-7192
DOI: 10.1016/j.ymgme.2010.11.078

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Skeletal improvement in patients with Ga

Skeletal improvement in patients with Gaucher disease type 1: a phase 2 trial of oral eliglustat

✍ Kamath, Ravi S.; Lukina, Elena; Watman, Nora; Dragosky, Marta; Pastores, Gregory 📂 Article 📅 2014 🏛 Springer 🌐 English ⚖ 554 KB

Improvement of bone disease by imiglucer

Improvement of bone disease by imiglucerase (Cerezyme) therapy in patients with skeletal manifestations of type 1 Gaucher disease: results of a 48-month longitudinal cohort study

✍ KB Sims; GM Pastores; NJ Weinreb; J Barranger; BE Rosenbloom; S Packman; P Kapla 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 207 KB

EDGE: A Phase 3 study evaluating once ve

EDGE: A Phase 3 study evaluating once versus twice daily dosing of eliglustat in patients with Gaucher disease type 1: interim results from the lead-in-period

✍ Charrow, Joel; Ida, Hiroyuki; Hollak, Carla; Amato, Dominick; Cravo, Renata; Kaw 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 52 KB

Safety and Efficacy of Velaglucerase Alf

Safety and Efficacy of Velaglucerase Alfa in Patients with Type 1 Gaucher Disease: 2 Years of Treatment in Phase III Trials and an Extension Study

✍ Ari Zimran; Madhulika Kabra; Pilar Giraldo; Marie-Françoise Ben Dridi; Deborah E 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 50 KB

A phase 3, randomized, double-blind, pla

A phase 3, randomized, double-blind, placebo-controlled, multi-center study to investigate the efficacy and safety of eliglustat in patients with Gaucher disease type 1 (ENGAGE): Results after 9months of treatment

✍ Mistry, Pramod; Lukina, Elena; Dridi, Marie-Françoise Ben; Amato, Dominick; Bari 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 77 KB

Oral modified insulin (HIM2) in patients

Oral modified insulin (HIM2) in patients with type 1 diabetes mellitus: results from a phase I/II clinical trial

✍ Stephen Clement; Paresh Dandona; J.Gordon Still; Gordana Kosutic 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 89 KB